Data from July 1st up to now. CoSS index, developed by Italian Society for Cardiac Surgery to monitor COVID-19 spread and diffusion. We are unfortunately going up again.
Tweets announcing that you enrolled a pt into a trial are better than industry ads w cakes.
But perhaps it’s best not to announce your belief that the industry product will be a game-changer.
I’m not a trialist, but I don’t think that’s how science should work
Another INTEGRITTY comment that raises some concerns related to a randomized trial on SAVR vs. TAVI (Evolut Low Risk 3yrs follow-up).
https://t.co/SdhDu8ZVLN
@VictorDayan1 Oh well many of drug eluting stents are made with antiproliferative/immunosuppressant drugs (e.g. rapamycin aka sirolimus) that may affect somehow these outcomes…
Data from July 1st up to now. CoSS index, developed by Italian Society for Cardiac Surgery to monitor COVID-19 spread and diffusion. We are unfortunately going up again.
When a government shares data you can derive useful tools. The CoSS which helps identifying when to restart elective surgery is now here on page 2. Thanks @intelw0rks https://t.co/Qb8bIoTB64